Brookstone Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,484
Closed -$24.9K – 1323
2026
Q2
$24.9K Sell
13,484
-806
-6% -$1.97K ﹤0.01% 1305
2026
Q1
$30.4K Buy
+14,290
New +$34K ﹤0.01% 1197

Other funds holding BDTX

Brookstone Capital Management's BDTX Position: Q3 2026 in Review

Brookstone Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q3 2026, closing a stake of 13,484 shares — an estimated $24.9K sold.

Brookstone Capital Management first reported a position in BDTX in Q1 2026 and held it in 2 quarters. The position peaked at $30.4K in Q1 2026. 111 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

  • Brookstone Capital Management reported no remaining Black Diamond Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Brookstone Capital Management sold 13,484 Black Diamond Therapeutics shares in Q3 2026, an estimated $24.9K.
  • Brookstone Capital Management first reported a position in Black Diamond Therapeutics in Q1 2026 and held it in 2 quarters.
  • Brookstone Capital Management's Black Diamond Therapeutics position peaked at $30.4K in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on Brookstone Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.